Flow Cytometry Shared Resource was established in 2004 to provide ready and affordable access to state-of- the-art multi-parameter cell analysis and sorting capabilities. This facility is comprised of a large number and variety of flow cytometry instruments that quantify the fluorescence of individual cells, typically following staining with specific antibodies. Flow cytometry has become an important tool in cancer research for many different purposes. Some important applications include the immune profiling of tumor microenvironment and the phenotyping of cancer cells. Cell sorting by Flow Cytometry is critical for the purification of cells for genomics, proteomics, metabolomics, or the isolation of tumor stem cells. This institutional resource serves the entire Yale School of Medicine (YSM) campus, including Yale Cancer Center (YCC), and thus has a critical mass of users supporting these large and expensive instruments. During the most recent funding period, 197 laboratories have used Flow Cytometry. Ninety-four of these users (48%) were YCC members. This Shared Resource was most widely used by the Genomics, Genetics and Epigenetics (GGE) and the Cancer Immunology (CI) Research Programs. A wide variety of assays are performed, and the laboratory also offers consulting on experimental protocols with its experienced full-time director. Flow cytometry has multiple applications in cancer research. For example, as the pace of research into cancer immunology and biologic therapies increases, defining the functional and phenotypic heterogeneity of mixed cell populations will continue to be a critical technology in cancer research. Flow cytometry is not only essential for cancer immunology research, but also empowers numerous other types of studies such as oncogenesis, cell signaling events, preclinical models, the assessment of therapeutic efficacy, gene editing using CRISPR and of course, cell sorting for genomic and RNA sequencing. Clearly, Flow Cytometry is vital to a number of programs within YCC.
The Specific Aims of Flow Cytometry are to: (1) Provide flow cytometry services that are of high quality, readily available, and at reasonable cost; (2) Educate the YCC community on the applications of flow cytometry in medical research; and (3) Collaborate with YCC investigators in the development of new applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989590
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications